Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
Global pharmaceutical major Lupin Limited announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. The tablets, available in multiple dosages including 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, entered the US market following the approval of its Abbreviated New Drug Application (ANDA) from the U.S. FDA. The product has been approved as bioequivalent to Xigduo® XR for the indications listed in the approved labeling.Lupin Limited, a global pharmaceutical leader headquartered in Mumbai, India, specializes in a wide range of products. Its portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has established a strong presence across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health, with products distributed in over 100 markets.
In terms of infrastructure, Lupin operates 15 state-of-the-art manufacturing sites and 7 research centers globally. The company relies on a dedicated workforce of over 24,000 professionals and is committed to improving patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LUPIN Stock Price Movement
As of 9:15 AM, shares of LUPIN LIMITED are slipping by 0.29% in live trading, currently at ₹2304.70. The stock is seeing a day's thin trading volume of 823 shares as it moves below its prior close of ₹2311.5.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.